Myriad Genetics Inc. (MYGN)

33.14
0.17 0.51
NASDAQ : Health Technology
Prev Close 33.31
Open 33.28
Day Low/High 32.71 / 33.51
52 Wk Low/High 17.50 / 41.57
Volume 119.50K
Avg Volume 688.20K
Exchange NASDAQ
Shares Outstanding 69.85M
Market Cap 2.29B
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Myriad's MyRisk® Hereditary Cancer Test Finds More Than 12 Percent Of Men With Prostate Cancer Carry An Inherited Genetic Mutation

Myriad's MyRisk® Hereditary Cancer Test Finds More Than 12 Percent Of Men With Prostate Cancer Carry An Inherited Genetic Mutation

Results from a Large 1,100 Patient Study Will Be Presented at the 2018 Genitourinary Cancer Symposium

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Jim Cramer focuses on S&P Global, Myriad Genetics, ProLogis, Emerson Electric, Ball Corp. and more.

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Jim Cramer says being a realistic investor doesn't mean being negative, especially when solid reality supports optimism.

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations For Hereditary Prostate Cancer

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations For Hereditary Prostate Cancer

Recommends all Metastatic Prostate Cancer Patients Receive Genetic Testing

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca

First Phase III PARP Inhibitor Clinical Trial to Use myChoice® HRD Plus as a Potential Companion Diagnostic

First Week of MYGN August 2018 Options Trading

Investors in Myriad Genetics, Inc. saw new options become available this week, for the August 2018 expiration.

Myriad Genetics Presents Results From Two Important EndoPredict® Studies At The 2017 San Antonio Breast Cancer Symposium

Myriad Genetics Presents Results From Two Important EndoPredict® Studies At The 2017 San Antonio Breast Cancer Symposium

Demonstrates that EndoPredict Predicts Response to Neoadjuvant Therapy in HR+ Breast Cancer

Myriad Genetics Presents Pivotal Validation Study For New RiskScore™ Test At The 2017 San Antonio Breast Cancer Symposium

Myriad Genetics Presents Pivotal Validation Study For New RiskScore™ Test At The 2017 San Antonio Breast Cancer Symposium

riskScore Demonstrates Highly Statistically-Significant Ability to Predict 5-Year and Lifetime Risk of Breast Cancer in Women Who Test Negative for Hereditary Breast Cancer Mutations

Myriad Collaborates With Department Of Veterans Affairs In Large Trial Evaluating The GeneSight® Test To Improve Mental Health Outcomes For Veterans

Myriad Collaborates With Department Of Veterans Affairs In Large Trial Evaluating The GeneSight® Test To Improve Mental Health Outcomes For Veterans

2,000 Patient Study Will Leverage GeneSight Test to Guide Therapy Selection

Myriad Announces GeneSight® Psychotropic Results From A Large Prospective Trial In Patients With Major Depressive Disorder

Myriad Announces GeneSight® Psychotropic Results From A Large Prospective Trial In Patients With Major Depressive Disorder

GeneSight Demonstrated Statistically Significant Improvement in the Gold Standard Clinical Outcomes of Remission and Response

37 Stocks That Will Probably Keep Nosediving

37 Stocks That Will Probably Keep Nosediving

When it comes to equities investing, recurrent patterns can be of enormous importance. But for these several dozen picks, the risk/reward issues are beyond just cyclical changes.

EndoPredict (EPclin) Shown In Second Study To Be More Effective Than Oncotype DX® (RS) In Women With Intermediate Risk Of Breast Cancer Recurrence

EndoPredict (EPclin) Shown In Second Study To Be More Effective Than Oncotype DX® (RS) In Women With Intermediate Risk Of Breast Cancer Recurrence

Myriad Announces Positive Results for an EndoPredict® Clinical Study at 3rd World Congress on Controversies in Breast Cancer

First Week Of December 15th Options Trading For Myriad Genetics (MYGN)

First Week Of December 15th Options Trading For Myriad Genetics (MYGN)

Investors in Myriad Genetics, Inc. saw new options begin trading this week, for the December 15th expiration.

GeneSight® Shown To Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response And Decrease Benzodiazepine Use

GeneSight® Shown To Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response And Decrease Benzodiazepine Use

Positive Results Presented at the 25th World Congress of Psychiatric Genetics

Myriad's BRACAnalysis CDx® Supplementary PMA Accepted By FDA For Review As A Companion Diagnostic For Lynparza® (olaparib) In Metastatic Breast Cancer

Myriad's BRACAnalysis CDx® Supplementary PMA Accepted By FDA For Review As A Companion Diagnostic For Lynparza® (olaparib) In Metastatic Breast Cancer

Company Expects FDA Priority Review to Conclude in the Fiscal Third-Quarter 2018

Short Interest Declines 13.2% For MYGN

Short Interest Declines 13.2% For MYGN

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,174,433 share decrease in total short interest for Myriad Genetics, Inc. , to 14,238,259, a decrease of 13.25% since 08/31/2017.

TheStreet Quant Rating: C+ (Hold)